Compare DraftKings Inc (DKNG) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DraftKings Inc vs ResMed Inc. — how do they compare? DraftKings Inc trades at $25.41 (market cap $12.51B), while ResMed Inc. trades at $195.51 (market cap $28.00B). The key difference: ResMed Inc. is far larger — about 2.2× DraftKings Inc's market cap, and ResMed Inc. pays a 1.24% dividend while DraftKings Inc pays none. Which is the better fit depends on your goals.
| DKNG | RMD | |
|---|---|---|
Market Cap | $12.51B | $28.00B |
Sector | Consumer Cyclical | Health |
52-Week High | $48.23 | $293.73 |
52-Week Low | $20.72 | $182.82 |
Enterprise Value | $13.43B | $27.18B |
Dividend Yield | — | 1.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DraftKings (DKNG) trades at $26.45, showing minimal daily movement. The stock exhibits a bullish technical trend with strong moving average signals, supported by a positive cash flow turnaround to $274.40 million in 2025. Revenue growth has been robust, rising from $2.2 billion in 2022 to $6.05 billion in 2025, with the company achieving its first net profit of $3.71 million. Recent expansion into Alberta and the launch of prediction markets highlight ongoing growth initiatives.
The outlook is positive, driven by analyst consensus with a $34.18 price target and 73% buy ratings. Key catalysts include upcoming sports events and product launches, but risks involve high valuation multiples and regulatory scrutiny. Profitability remains nascent, requiring sustained execution to justify current premiums.
ResMed (RMD) trades at $198.50, down 2.63% on the day, with technical indicators showing a bearish trend near support at $197. The company demonstrates strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $2.86 versus $2.80 expected, and robust profitability with a 27.44% net margin. Recent strategic moves include the sale of its MatrixCare business for $490 million to sharpen focus on core sleep and respiratory care markets.
The outlook remains positive given analyst consensus targets near $249.57, representing significant upside, though near-term technical weakness and competitive pressures in digital health pose risks. Revenue growth is projected to reach $5.5 billion in 2026, supporting a solid investment case for long-term holders despite current bearish momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DraftKings Inc
DraftKings Inc is a digital sports entertainment and gaming company. The company provides users with daily fantasy sports (DFS), sports betting, and iGaming opportunities and is also involved in the design & development of sports betting and casino gaming platform software for online and retail sportsbook and casino gaming products. It operates in two segments: Business-to-consumer(B2C) and Business-to-Business(B2B), of which the vast majority of its revenue comes from the B2C segment. Geographically, it derives most of its revenue from the United States.
Read more on DKNG →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
